Business
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms
BOSTON, March 18, 2026--Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sankyo (TSE: 4568) to support research efforts in advanced biologics.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a shared interest in exploring innovative discovery approaches that may enable the generation and evaluation of antibody-based biologics across multiple therapeutic areas, and further supports Leveragen’s strategy of working with leading pharmaceutical and biotechnology companies to apply its in vivo discovery platforms in early-stage research and preclinical development.","displaySize":"","headline":null,"caption":"Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a shared interest in exploring innovative discovery approaches that may enable the generation and evaluation of antibody-based biologics across multiple therapeutic areas, and further supports Leveragen’s strategy of working with leading pharmaceutical and biotechnology companies to apply its in vivo discovery platforms in early-stage research and preclinical development.","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/ede41077ae5ae8dceb715dda2f027383"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fL17nOHQRYXfRr0bMA4_Eg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ede41077ae5ae8dceb715dda2f027383","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":220,"url":"https://media.zenfs.com/en/business-wire.com/a873f5889de8f6f03a222e0bc44eed3e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4claRDPzcE6nyYuUqfs0mQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a873f5889de8f6f03a222e0bc44eed3e","width":480,"height":220}}},{"type":"text","content":"BOSTON, March 18, 2026--(BUSINESS WIRE)--Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sa...